The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.

Translocations of the mixed lineage leukemia (MLL) gene occur in 60% to 80% of all infant acute leukemias and are markers of poor prognosis. MLL-AF9 and other MLL fusion proteins aberrantly recruit epigenetic regulatory proteins, including histone deacetylases (HDAC), histone methyltransferases, bromodomain-containing proteins, and transcription elongation factors to mediate chromatin remodeling and regulate tumorigenic gene expression programs. We conducted a small-molecule inhibitor screen to test the ability of candidate pharmacologic agents targeting epigenetic and transcriptional regulatory proteins to induce apoptosis in leukemic cells derived from genetically engineered mouse models of MLL-AF9-driven acute myeloid leukemia (AML). We found that the CDK inhibitor dinaciclib and HDAC inhibitor panobinostat were the most potent inducers of apoptosis in short-term in vitro assays. Treatment of MLL-rearranged leukemic cells with dinaciclib resulted in rapidly decreased expression of the prosurvival protein Mcl-1, and accordingly, overexpression of Mcl-1 protected AML cells from dinaciclib-induced apoptosis. Administration of dinaciclib to mice bearing MLL-AF9-driven human and mouse leukemias elicited potent antitumor responses and significantly prolonged survival. Collectively, these studies highlight a new therapeutic approach to potentially overcome the resistance of MLL-rearranged AML to conventional chemotherapies and prompt further clinical evaluation of CDK inhibitors in AML patients harboring MLL fusion proteins.

• Publication year

  2016

• Venue

  Cancer Research

• Publication date

  2016-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-15-1070PMID 26627013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute Myeloid Leukaemia: New Targets and Therapies

  2017influential reference
• Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

  2017cited by this paper
• Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.

  2016cited by this paper
• Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.

  2015cited by this paper
• Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice

  2015cited by this paper
• Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients

  2014cited by this paper
• The structure and substrate specificity of human Cdk12/Cyclin K

  2014cited by this paper
• CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo

  2014cited by this paper
• CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma

  2014influential reference
• Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors.

  2014influential reference
• Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia

  2014cited by this paper
• Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

  2014cited by this paper
• Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

  2013cited by this paper
• Gene mutations of acute myeloid leukemia in the genome era

  2013cited by this paper
• Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas.

  2013cited by this paper
• Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

  2013influential reference
• Deregulations in the Cyclin-Dependent Kinase-9-Related Pathway in Cancer: Implications for Drug Discovery and Development

  2013cited by this paper
• A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

  2013cited by this paper
• The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling

  2013cited by this paper
• HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses

  2013cited by this paper
• Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities

  2013cited by this paper
• Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.

  2013cited by this paper
• Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains.

  2013cited by this paper
• Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

  2013cited by this paper
• Delving deeper: MCL-1's contributions to normal and cancer biology.

  2013cited by this paper
• Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.

  2013cited by this paper
• Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)

  2012cited by this paper
• Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.

  2012cited by this paper
• Transcriptional amplification in tumor cells with elevated c-Myc.

  2012cited by this paper
• c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells.

  2012cited by this paper
• Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia.

  2012cited by this paper
• The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.

  2012cited by this paper
• Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

  2011influential reference
• The super elongation complex (SEC) and MLL in development and disease.

  2011cited by this paper
• The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine

  2011cited by this paper
• Mechanisms of Action of a Dual Cdc7/Cdk9 Kinase Inhibitor against Quiescent and Proliferating CLL Cells

  2011cited by this paper
• RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

  2011influential reference
• Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

  2011influential reference
• An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.

  2011cited by this paper
• The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells

  2011cited by this paper
• Targeting epigenetic programs in MLL-rearranged leukemias.

  2011cited by this paper
• Transcriptional and epigenetic networks in haematological malignancy

  2011influential reference
• MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.

  2011cited by this paper
• A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription.

  2010cited by this paper
• Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis.

  2010cited by this paper
• The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis.

  2010cited by this paper
• Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

  2010cited by this paper
• Mouse models of human AML accurately predict chemotherapy response.

  2009cited by this paper
• The molecular biology of mixed lineage leukemia

  2009influential reference
• Loss of MLL PHD finger 3 is necessary for MLL-ENL-induced hematopoietic stem cell immortalization.

  2008influential reference
• MLL translocations, histone modifications and leukaemia stem-cell development

  2007cited by this paper
• Protein arginine-methyltransferase-dependent oncogenesis

  2007cited by this paper
• Acute Myeloid Leukemia: Epidemiology and Etiology

  2006influential reference
• Acute myeloid leukaemia.

  2006cited by this paper
• Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.

  2005influential reference
• Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.

  2005cited by this paper
• c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis

  2003cited by this paper
• The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.

  2002cited by this paper
• Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

  2001cited by this paper
• The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway

  2001cited by this paper
• c-Myc Mediates Activation of the cad Promoter via a Post-RNA Polymerase II Recruitment Mechanism*

  2001cited by this paper
• Characterization of murine hemopoietic-supportive (MS-1 and MS-5) and non-supportive (MS-K) cell lines.

  1992cited by this paper
• A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry.

  1991cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper

• Dinaciclib reduces MCL-1 levels and triggers apoptosis in adult T-cell leukemia/lymphoma.

  2026cites this paper
• Novel RNA Polymerase I and Cyclin Dependent Kinase combination therapy for the treatment of aggressive Acute Myeloid Leukemia

  2025influential citation
• A CDK11-dependent RNA polymerase II pause-checkpoint precedes CDK9-mediated transition to transcriptional elongation.

  2025cites this paper
• Cyclin Dependent Kinases in Antiviral Drug Discovery.

  2025cites this paper
• SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosis.

  2025cites this paper
• TP53-Agnostic Lethality through Combined Pan-HDAC and CDK Inhibition in Acute Myeloid Leukemia.

  2025cites this paper
• Tumour Cell Size Control and Its Impact on Tumour Cell Function

  2025cites this paper
• Discovery of a Novel Dihydroisoquinolinone Derivative as a Potent CDK9 Inhibitor Capable of Overcoming L156F Mutant for the Treatment of Hematologic Malignancies.

  2025cites this paper
• Polyamine depletion limits progression of acute leukaemia

  2025cites this paper
• Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia

  2025cites this paper
• Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer

  2025cites this paper
• Factors affecting response and resistance to venetoclax in acute myeloid leukemia

  2025cites this paper
• Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia

  2024cites this paper
• Establishing a cryopreserved biobank of living tumor tissues for drug sensitivity testing

  2024cites this paper
• Targeting Molecular Signaling Pathways and Cytokine Responses to Modulate c-MYC in Acute Myeloid Leukemia.

  2024cites this paper
• Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia

  2024cites this paper
• Discovery of a potent CDKs/FLT3 PROTAC with enhanced differentiation and proliferation inhibition for AML.

  2024cites this paper
• Novel meriolin derivatives activate the mitochondrial apoptosis pathway in the presence of antiapoptotic Bcl-2

  2024cites this paper
• The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling

  2024cites this paper
• MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer

  2024cites this paper
• RNA decay defines the response to transcriptional perturbation in leukaemia

  2023cites this paper
• Dinaciclib inhibits the growth of acute myeloid leukemia cells through either cell cycle-related or ERK1/STAT3/MYC pathways.

  2023cites this paper
• Development and validation of a sensitive UPLC-MS/MS analytical method for GFH009 in rat plasma and its application to toxicokinetics studies.

  2023cites this paper
• Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression

  2023cites this paper
• SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML

  2023cites this paper
• 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) induces apoptosis in breast cancer cells through inhibiting of Mcl-1 expression

  2023cites this paper
• Establishment of a t(11;19), KMT2A Rearranged B-ALL Cell Line for Preclinical Evaluation and Novel Therapeutics Development for Refractory Infant Leukemia

  2023cites this paper
• Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments

  2023cites this paper
• A new cyclin-dependent kinase-9 inhibitor A09-003 induces apoptosis in acute myeloid leukemia cells with reduction of myeloid cell leukemia sequence-1 protein.

  2023cites this paper
• Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy

  2023cites this paper
• Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting.

  2023cites this paper
• An Overview of CDK Enzyme Inhibitors in Cancer Therapy.

  2023cites this paper
• Targeting regulated cell death pathways in acute myeloid leukemia

  2023cites this paper
• Discovery of novel and bioavailable histone deacetylases and cyclin-dependent kinases dual inhibitor to impair the stemness of leukemia cells.

  2023cites this paper
• The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression

  2022cites this paper
• Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma

  2022cites this paper
• Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia

  2022cites this paper
• CDK9 inhibitors in cancer research.

  2022cites this paper
• Targeting OXPHOS de novo purine synthesis as the nexus of FLT3 inhibitor–mediated synergistic antileukemic actions

  2022cites this paper
• Inhibition of pyrimidine biosynthesis targets protein translation in AML

  2021cites this paper
• Gene Transcription as a Therapeutic Target in Leukemia

  2021cites this paper
• Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches

  2021cites this paper
• Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models

  2021influential citation
• The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.

  2021cites this paper
• CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents

  2021cites this paper
• The application of BH3 mimetics in myeloid leukemias

  2021cites this paper
• CDK inhibitors in cancer therapy, an overview of recent development.

  2021cites this paper
• Targeting Chromatin Regulation in Acute Myeloid Leukemia

  2021cites this paper
• Inhibition of the CDK9–cyclin T1 protein–protein interaction as a new approach against triple-negative breast cancer

  2021cites this paper
• Targeting transcription cycles in cancer

  2021cites this paper
• Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline

  2021cites this paper
• BH3 Mimetics in AML Therapy: Death and Beyond?

  2020cites this paper
• P-TEFb as A Promising Therapeutic Target

  2020cites this paper
• Spt5 Phosphorylation and the Rtf1 Plus3 Domain Promote Rtf1 Function through Distinct Mechanisms

  2020cites this paper
• MLL-Rearranged Acute Lymphoblastic Leukemia

  2020cites this paper
• Synergistic Anti Leukemia Effect of a Novel Hsp90 and a Pan Cyclin Dependent Kinase Inhibitors

  2020cites this paper
• Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition

  2020cites this paper
• CDK13 cooperates with CDK12 to control global RNA polymerase II processivity

  2020cites this paper
• Prediction of therapeutic outcome and survival in a transgenic mouse model of pancreatic ductal adenocarcinoma treated with dendritic cell vaccination or CDK inhibitor using MRI texture: a feasibility study.

  2020cites this paper
• A PP2A-Integrator complex fine-tunes transcription by opposing CDK9

  2020cites this paper
• MLLT10 rearranged acute leukemia: Incidence, prognosis, and possible therapeutic strategies

  2020cites this paper
• Targeting CDK9: A novel biomarker in the treatment of endometrial cancer

  2020cites this paper
• CDK13 cooperates with CDK12 to control global RNA polymerase II processivity

  2020cites this paper
• The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

  2020cites this paper
• CDK12: a potential therapeutic target in cancer.

  2020cites this paper
• Targeting LSD1 for acute myeloid leukemia (AML) treatment.

  2020cites this paper
• Pharmacological inactivation of CDK2 inhibits MYC/BCL-XL-driven leukemia in vivo through induction of cellular senescence

  2020cites this paper
• Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism

  2019cites this paper
• The mechanism of MYB transcriptional regulation by MLL-AF9 oncoprotein

  2019cites this paper
• Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia

  2019cites this paper
• A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies

  2019cites this paper
• The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?

  2019cites this paper
• AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells

  2019cites this paper
• Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy

  2019cites this paper
• A kinase-independent role for CDK8 in BCR-ABL1+ leukemia

  2019cites this paper
• Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach

  2019cites this paper
• Targeting CDK9 for treatment of colorectal cancer

  2019cites this paper
• Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression

  2019cites this paper
• Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches

  2019cites this paper
• Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.

  2019cites this paper
• Venetoclax-based therapies for acute myeloid leukemia.

  2019cites this paper
• CDK9 as an Appealing Target for Therapeutic Interventions.

  2019cites this paper
• Identification and targeting of novel CDK9 complexes in acute myeloid leukemia.

  2019cites this paper
• AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces 1 apoptosis in hematological cancer cells 2

  2019cites this paper
• AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces 1 apoptosis in hematological cancer cells 2

  2019cites this paper
• Cyclin‐dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer

  2019cites this paper
• Sensitivity and Resistance to BH3 Mimetics in Cancer Therapy

  2018cites this paper
• CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia

  2018cites this paper
• Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target

  2018cites this paper
• Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma

  2018cites this paper
• Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile

  2018cites this paper
• Identification of crucial genes associated with esophageal squamous cell carcinoma by gene expression profile analysis

  2018cites this paper
• Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2.

  2018cites this paper
• BRD4 facilitates replication stress-induced DNA damage response

  2018cites this paper
• Dinaciclib induces immunogenic cell death and enhances anti-PD1–mediated tumor suppression

  2018cites this paper
• Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

  2018cites this paper
• CDK9 inhibitors in acute myeloid leukemia

  2018cites this paper
• Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma

  2017cites this paper
• The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE.

  2017cites this paper
• Emerging cell cycle inhibitors for acute myeloid leukemia

  2017cites this paper